These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 24553361)

  • 21. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Rajaratnam G; Edwards J
    Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
    [No Abstract]   [Full Text] [Related]  

  • 22. Bone metabolism during long-term treatment with imatinib.
    O'Sullivan S; Horne A; Wattie D; Porteous F; Gamble G; Browett P; Grey A
    Leuk Lymphoma; 2013 Aug; 54(8):1783-5. PubMed ID: 23278638
    [No Abstract]   [Full Text] [Related]  

  • 23. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Barbour V
    Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
    [No Abstract]   [Full Text] [Related]  

  • 24. Chronic myelogenous leukemia therapy beyond imatinib.
    Deininger M
    Clin Adv Hematol Oncol; 2010 Mar; 8(3):178-80. PubMed ID: 20400933
    [No Abstract]   [Full Text] [Related]  

  • 25. Part I: Milestones in personalised medicine--imatinib.
    Gambacorti-Passerini C
    Lancet Oncol; 2008 Jun; 9(6):600. PubMed ID: 18510992
    [No Abstract]   [Full Text] [Related]  

  • 26. [Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
    Sawadogo S; Hien FM; Ouédraogo MS; Drabo YJ
    Pan Afr Med J; 2014; 18():142. PubMed ID: 25419280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
    Campillo-Recio D; Perez-Rodriguez L; Yebra E; Cervero-Jimenez M
    Rev Clin Esp (Barc); 2014 May; 214(4):231-2. PubMed ID: 24564991
    [No Abstract]   [Full Text] [Related]  

  • 28. Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
    Wolf D
    Eur J Haematol; 2015 Mar; 94(3):189-90. PubMed ID: 25712068
    [No Abstract]   [Full Text] [Related]  

  • 29. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
    Imataki O
    Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
    [No Abstract]   [Full Text] [Related]  

  • 30. [THE STUDY OF RESPONSE TO TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA DEPENDING ON SOCAL SCORE].
    T P; L D
    Lik Sprava; 2015; (1-2):97-102. PubMed ID: 26118036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
    Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
    [No Abstract]   [Full Text] [Related]  

  • 32. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
    Otrock ZK; Mahfouz RA; Fahed Z; Farhat FS; Ziade A; Nasr F; Kassem N; Abboud MR
    Int J Hematol; 2012 Oct; 96(4):521-4. PubMed ID: 22961257
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
    Erba HP
    Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 35. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

  • 36. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
    Sandoval C; Giamelli J; Jayabose S
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):507-8. PubMed ID: 12794534
    [No Abstract]   [Full Text] [Related]  

  • 37. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia.
    Jiang Q; Xu LP; Liu DH; Liu KY; Gale RP; Zhang MJ; Jiang B; Zhang XH; Wang Y; Chen SS; Zhao XY; Chen H; Jiang H; Chen YH; Han W; Qin YZ; Liu YR; Lai YY; Lv M; Huang XJ
    Leukemia; 2013 Dec; 27(12):2410-3. PubMed ID: 23698276
    [No Abstract]   [Full Text] [Related]  

  • 39. Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel.
    Yamazaki R; Aisa Y; Mori T; Iketani O; Ikeda Y; Okamoto S
    Leuk Lymphoma; 2009 Apr; 50(4):670-2. PubMed ID: 19373671
    [No Abstract]   [Full Text] [Related]  

  • 40. Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia.
    Vander Velde N; Chen L; Guo A; Sharma H; Marynchenko M; Wu EQ; Liu J; Yang H; Shi L
    J Oncol Pract; 2013 Sep; 9(5):e212-9. PubMed ID: 23943889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.